Keith's Story

Listen in how one CRC patient and his physician used Signatera as a part of his treatment strategy to help identify an early signal that cancer may be lurking.

Signatera Ordering

Powering Precision: The essential role of ctDNA testing for MRD assessment in GI malignancies

In this webinar, we explore how ctDNA can help bring clarity to common clinical scenarios including adjuvant treatment decision making, indeterminate findings and assessing treatment response.

3988 - Natera - Tampa - Breast Cancer V6e (1)

SABCS 2022 Product Theater Section 1 - The Cycle of ctDNA in Breast Cancer

SABCS 2022 Product Theater Section 5 - Limitations and Eblis

Clinical Applications for Signatera in Breast Cancer Surveillance

SABCS 2022 Product Theater Section 4 - Example Case

Real World Case Study: Personalized ctDNA Testing for High Risk Breast Cancer Surveillance

SABCS 2022 Product Theater Section 3 - ctDNA Utility

Clinical utility of personalized ctDNA testing in breast cancer treatment

SABCS 2022 Product Theater Section 2 - MRD

Clinical applications of ctDNA testing for MRD assessment in breast cancer

Monitoring ctDNA in Breast Cancer: Moving on with life with Signatera

New ctDNA GU cancers data: improve patient management in bladder and kidney

Webinar presents new ctDNA data from ASCOGU in muscle invasive bladder cancer and metastatic renal cell carcinoma

Optimize breast cancer management: Incorporating personalized ctDNA testing into your practice

Clinical applications to support management of patients with high risk breast cancer

Know Cancer’s Next Move: Using ctDNA to guide treatment decisions in patients with GI Cancer

This webinar will explore the expanding role of circulating tumor DNA (ctDNA) for assessing molecular residual disease (MRD) and monitoring treatment response in patients with colorectal cancer.

ctDNA in GI Cancers

Applications of personalized ctDNA testing to optimize treatment decisions in patients with GI cancers, presented by Dr. Adham Jurdi, MD

Webinar: Latest data using ctDNA to assess breast cancer recurrence risk and treatment response

Signatera in advanced CRC - Open Captions

Signatera in advanced CRC

Trevor's Story

Natera Oncology Portfolio